A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease
Abstract Background Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4). An extension study (TEMPO 4:4) showed continued delay in progression...
Main Authors: | Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L. Barnett, Dorothee Oberdhan, Terry Watnick, Stephen Seliger |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12882-022-02956-8 |
Similar Items
-
Mortality risk in patients with autosomal dominant polycystic kidney disease
by: Deirdre Mladsi, et al.
Published: (2024-02-01) -
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
by: Sans-Atxer L, et al.
Published: (2018-01-01) -
Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
by: Kyohei Kunizawa, et al.
Published: (2018-03-01) -
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
by: Michael Lioudis, et al.
Published: (2023-06-01) -
Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
by: Hee Sun Beak, et al.
Published: (2023-12-01)